A. Ernest WhitonChief Financial OfficerZOLL Medical Corporation+1 (978) 421-9655
Diane EganZOLL Medical Corporation+1 (978) firstname.lastname@example.org
FOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE
20 AutoPulse Devices Part of a ₤1 Million Order fromEssexAmbulance Service NHS Trust
June 7, 2006 — CHELMSFORD ,MASS.—ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and related software solutions, today reported that Essex Ambulance Service NHS Trust (Essex Ambulance) has purchased more than £1 million (approximately USD $1.8 million) of ZOLL resuscitation equipment. The order was received at the very end of the second quarter of ZOLL’s fiscal 2006, and it is expected to ship in Q3. The order includes 20 ZOLL AutoPulse® Non-invasive Cardiac Support Pumps, the largest single U.K. AutoPulse order to date. In addition, Essex Ambulance purchased 90 ZOLL E Series™ and 90 ZOLL AED Pro® defibrillators.
Rob Ashford, Locality General Manager for Essex Ambulance, noted that his crews had tested a number of competing devices over a four-month period. The overwhelming majority voted for ZOLL as the devices they wished to use in the field.
With respect to the AutoPulse, Mr. Ashford said, “We believe this device can improve blood flow during sudden cardiac arrest. It can move much more blood than could ever be done with human hands during CPR. It also offers the benefit of freeing up paramedics and technicians to focus on other life-saving interventions. We are excited at the prospect of using these devices to help rescue staff be more effective in the field.”
“We are pleased that the NHS staff chose our products over the competition,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “This agreement demonstrates wider international acceptance for the AutoPulse, as well as for our newer defibrillator offerings. Moreover, customers understand the benefit of using ZOLL products in an integrated fashion. We believe that such an integrated approach will help professional rescuers improve their resuscitation efforts.”
ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.
ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East, Asia, and Australia. For more information, visit www.zoll.com or call +1 (978) 421-9655.
Certain statements contained in this press release regarding matters that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, ZOLL’s ability to compete in the resuscitation business; acceptance of the AutoPulse and its recently launched products; changes in regulations affecting the healthcare industry; global economic conditions; and those other factors discussed in the section entitled “Risk Factors” in ZOLL’s Annual Report on Form 10-Q, which was filed with the SEC on May 12, 2006.
©2006 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. E Series is a trademark of ZOLL Medical Corporation. AED Pro, AutoPulse, and ZOLL are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.